Program
sintilimab
Also written as “Sintilimab”, “IBI308” and “IBI939+ Sintilimab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Colorectal Neoplasms · Esophageal Squamous Cell Carcinoma, led by 10 companies.
Drug pageSintilimab: every studyMany companies study it; this page follows only the 40 they lead. All 403 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologicsits history only | 295 open or running | phase 3since May 7, 2017 | Oct 8, 2016 | Mar 25, 2030phase 3 · NCT07917468 |
| HUTCHMEDits history only | 31 open or running | phase 3since Aug 16, 2022 | Mar 27, 2019 | Jan 8, 2029phase 3 · NCT06584032 |
| Beijing Aosaikang Pharmaceuticalits history only | 11 open or running | phase 2since Nov 21, 2022 | Nov 21, 2022 | none ahead |
| Chipscreen Biosciences | 11 open or running | phase 3since Jun 28, 2024 | Jun 28, 2024 | May 31, 2028phase 3 · NCT06497985 |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 2since Jul 30, 2026 | Jul 30, 2026 | Sep 30, 2029phase 2 · NCT07761286 |
| Sichuan Luzhou Buchang Biopharmaceuticalits history only | 11 open or running | phase 1since Jan 2, 2025 | Jan 2, 2025 | none ahead |
| Simcere Pharmaceutical Groupits history only | 10 open or running | phase 1since Jan 29, 2023 | Jan 29, 2023 | none ahead |
| Suzhou Zelgen Biopharmaceuticalsits history only | 11 open or running | phase 2since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| TaiRxits history only | 11 open or running | phase 2since Mar 31, 2026 | Mar 31, 2026 | Dec 31, 2027phase 2 · NCT07521852 |
| TJ Biopharmaits history only | 11 open or running | phase 2since May 21, 2025 | May 21, 2025 | none ahead |
Also a collaborator on its studies: Fortrea.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chipscreen Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named sintilimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, IBI308
- Jun 28, 2024First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT06497985 · 430 planned · China
Ahead
- May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT06497985
TargetBeta
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The one study Chipscreen Biosciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06497985Colorectal Neoplasms · China | 3 | Recruiting | May 31, 2028 | 430 |
How it is read
Names in the registry
- “Sintilimab”, 15 entries
- “IBI308”, 5 entries
- “IBI939+ Sintilimab”, 2 entries
- “IBI110+ Sintilimab”, 2 entries
- “fruquintinib+sintilimab”, 1 entry
Codes read as this program: IBI308.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Hepatocellular, 4 studies
- Stomach Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Esophageal Squamous Cell Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.